Journal article
Treatment options in non-muscle-invasive bladder cancer after BCG failure
Indian journal of urology, Vol.31(4), pp.312-319
2015
DOI: 10.4103/0970-1591.166475
PMCID: PMC4626915
PMID: 26604442
Abstract
Bladder cancer is the ninth-most prevalent cancer worldwide. Most patients with urothelial cell carcinoma of the bladder present with non-muscle-invasive disease and are treated with bacillus Calmette-Guérin (BCG) intravesical therapy. Many of these patients experience disease recurrence after BCG failure. Radical cystectomy is the recommended treatment for high-risk patients failing BCG. However, many patients are unfit for or unwilling to undergo this procedure. We searched the published literature on the treatment of non-muscle-invasive bladder cancer (NMIBC) after BCG failure. We review current evidence regarding intravesical therapy with gemcitabine, mitomycin combined with thermo-chemotherapy, docetaxel, nab-paclitaxel, photodynamic therapy (PDT), BCG with interferon (IFN), and combination sequentially administered chemotherapy.
Details
- Title: Subtitle
- Treatment options in non-muscle-invasive bladder cancer after BCG failure
- Creators
- Nathan A Brooks - Department of Urology, The University of Iowa, Iowa, USAMichael A O’Donnell - Department of Urology, The University of Iowa, Iowa, USA
- Resource Type
- Journal article
- Publication Details
- Indian journal of urology, Vol.31(4), pp.312-319
- DOI
- 10.4103/0970-1591.166475
- PMID
- 26604442
- PMCID
- PMC4626915
- NLM abbreviation
- Indian J Urol
- ISSN
- 0970-1591
- eISSN
- 1998-3824
- Publisher
- Medknow Publications & Media Pvt Ltd; India
- Language
- English
- Date published
- 2015
- Academic Unit
- Urology
- Record Identifier
- 9984051899602771
Metrics
18 Record Views